STOCK TITAN
  1. Home
  2. News
  3. MRKR

Marker Therapeutics Inc - MRKR STOCK NEWS

Welcome to our dedicated news page for Marker Therapeutics (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marker Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marker Therapeutics's position in the market.

News
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
Rhea-AI Summary
Marker Therapeutics, Inc. presents promising preliminary data from the APOLLO study at the 11th Global Summit on Hematologic Malignancies. The study focuses on MT-601, a multiTAA-specific T cell product, for lymphoma patients who failed anti-CD19 CAR T cell therapy. Results show durable objective responses and sustained complete responses, highlighting potential benefits of MT-601.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences clinical trial
-
News
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) reports positive results in lymphoma program with sustained complete response, secures $2 million NIH funding for AML program, receives ODD from EMA for AML treatment, appoints new leadership, and executes non-dilutive agreement with Cell Ready to reduce expenses and extend runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.74%
Tags
earnings
-
News
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) announced that its CEO, Juan Vera, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024, discussing the company's advancements and clinical development programs. The conference will provide insights into Marker's business and future milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
conferences
News
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Rhea-AI Summary
Nimbus Therapeutics appoints Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of pharmaceutical research and development experience. Dr. Knobil's expertise will aid in accelerating Nimbus' development programs in oncology, immunology, and metabolism, aiming to bring novel therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
management
-
News
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) announced the approval of 'neldaleucel' as the nonproprietary name for MT-601, a T cell product candidate for the treatment of lymphoma. The approval signifies a significant milestone in the development of multiTAA therapies, following positive clinical safety and durability results in the Phase 1 study. Juan Vera, M.D., President and CEO of Marker Therapeutics, expressed the importance of the approval in advancing potential treatments for patients with lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
News
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Rhea-AI Summary
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced strategic prioritization of clinical programs with a focus on MT-601 in patients with lymphoma. The company also provided updates supporting the clinical benefits of MT-401 in patients with measurable residual disease (MRD) in acute myeloid leukemia (AML).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
News
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
Rhea-AI Summary
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced its participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit alongside the J.P. Morgan 42nd Annual Healthcare Conference 2024. The company secured over $17 million in non-dilutive funding and will present at the summit. Members of the management team will also conduct one-on-one meetings with investors during J.P. Morgan week.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
-
News
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) reports positive clinical update on APOLLO study, with patient maintaining complete response six months after MT-601 treatment for relapsed Non-Hodgkin’s Lymphoma following anti-CD19 CAR T cell therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.73%
Tags
none
-
News
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) reports positive clinical outcomes for MT-601 in lymphoma and ODD from EMA for MT-401 in AML. Financially, Marker reported a net loss of ($3.0) million for the quarter ended September 30, 2023, compared to a net loss of ($6.9) million in the same period of 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
earnings
News
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
Rhea-AI Summary
Marker Therapeutics reports positive clinical updates in APOLLO trial for lymphoma treatment with MT-601
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.41%
Tags
none
Stock MRKR logo
Marker Therapeutics Inc

Nasdaq:MRKR

MRKR Rankings

#4869 Ranked by Market Cap
#4373 Ranked by Stock Gains
N/A Ranked by Dividends

MRKR Stock Data

38.37M
6.75M
12.17%
22.95%
1.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Jacksonville

About MRKR

tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). the company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer t-cells and helper t-cells to destroy cancer cells, and they are designed to work with 80% of the population. tapimmune is advancing two clinical stage t-cell vaccine candidates in multiple phase ii and phase ib/iia clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from fda fast track and orphan disease designation. the company is working in collaboration with industry and clini